Last reviewed · How we verify
Octapressin (FELYPRESSIN)
Octapressin (generic name: FELYPRESSIN) is a drug. It is currently in Phase 2 development for Local anesthesia.
Octapressin works by binding to the vasopressin V1a receptor, which blocks pain signals to the brain.
Octapressin, also known as Felypressin, is a small molecule modality targeting the vasopressin V1a receptor. It is used for local anesthesia and is currently owned by a pharmaceutical company. The exact commercial status of Octapressin is unknown, but it is not off-patent. Key safety considerations include its potential effects on blood pressure and cardiac function. As a local anesthetic, it works by blocking pain signals to the brain.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | FELYPRESSIN |
|---|---|
| Target | Vasopressin V1a receptor |
| Modality | Recombinant protein |
| Therapeutic area | Pain |
| Phase | Phase 2 |
Mechanism of action
Imagine your nerves are like messengers sending signals to your brain. Octapressin blocks these messengers from reaching the brain, which prevents pain signals from being received. This helps to numb the area and reduce pain.
Approved indications
- Local anesthesia
Common side effects
Key clinical trials
- Comparison of Articaine and Prilocaine for Extraction of Maxillary Teeth (PHASE4)
- Anesthetic Efficacy of Liposomal Prilocaine in Maxillary Infiltration Anesthesia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Octapressin CI brief — competitive landscape report
- Octapressin updates RSS · CI watch RSS
Frequently asked questions about Octapressin
What is Octapressin?
How does Octapressin work?
What is Octapressin used for?
What is the generic name of Octapressin?
What development phase is Octapressin in?
What does Octapressin target?
Related
- Target: All drugs targeting Vasopressin V1a receptor
- Therapeutic area: All drugs in Pain
- Indication: Drugs for Local anesthesia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing